Detalles de la búsqueda
1.
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Ann Oncol
; 34(3): 262-274, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36535565
2.
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.
Ann Oncol
; 34(3): 251-261, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36535566
3.
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancerâ.
Ann Oncol
; 33(2): 169-180, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34800678
4.
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
Ann Oncol
; 33(5): 466-487, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35176458
5.
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.
Ann Oncol
; 32(3): 395-403, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33276076
6.
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Ann Oncol
; 31(4): 507-516, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32139298
7.
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Ann Oncol
; 31(7): 902-911, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32320754
8.
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Ann Oncol
; 31(10): 1397-1404, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32634610
9.
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Ann Oncol
; 31(11): 1536-1544, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32861806
10.
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.
Ann Oncol
; 30(11): 1831-1839, 2019 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31501887
11.
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
Ann Oncol
; 30(2): 281-289, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30657853
12.
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.
Ann Oncol
; 29(3): 687-693, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29293889
13.
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
Ann Oncol
; 28(4): 874-881, 2017 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28168303
14.
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Ann Oncol
; 28(2): 292-297, 2017 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27803005
15.
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
Ann Oncol
; 28(6): 1250-1259, 2017 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28460066
16.
Osimertinib in central nervous system progressive EGFR-mutant lung cancer: do we need to detect T790M?
Ann Oncol
; 31(11): 1582, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32890631
17.
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing.
Ann Oncol
; 26(1): 161-166, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25355724
18.
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
Ann Oncol
; 26(10): 2066-72, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26153496
19.
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer.
Ann Oncol
; 26(4): 762-768, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25538174
20.
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC).
Ann Oncol
; 26(5): 894-901, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25722381